Active ingredient: Favipiravir
Manufacturer : Glenmark Gracewell Division
Product Code: Favipiravir-1
What is Fabiflu (Favipiravir)?
Favipiravir is a drug that was initially used for the treatment of resistant cases of influenza. It shows
activity against more than one virus, including the influenza A and B and may also be effective
against avian influenza resistant to other medicines. Investigations have been conducted for the
treatment of serious viral diseases such as Lassa virus, Ebola virus, and now coronavirus disease
2019 (COVID-19) with favipiravir. The drug works by inhibiting the replication of the virus. 
In countries like India, Japan, and Saudi Arabia, favipiravir has been approved for the treatment of
mild-to-moderate COVID-19 infection and is available in the form of oral tablets.
Fabiflu (Favipiravir) Classification and Mechanism of Action
Favipiravir belongs to the anti-viral class of drugs. It is administered orally in the inactive form, and
undergoes a reaction in the body, which converts it into its active form known as favipiravir-RTP.
This active drug molecule inhibits the action of an enzyme known as RNA polymerase, which is
required for the replication of the virus, thus preventing viral replication.
Looking after Fabiflu (Favipiravir)
Store favipiravir tablets in a cool, dry place where children cannot reach them.
Treatment with favipiravir lasts for a maximum of 14 days. The adult dosage for favipiravir is as
Day 1: 1800 mg of favipiravir to be taken twice a day (9 tablets of 200 mg each in the
morning and 9 in the evening)
Days 2-14: 800 mg of favipiravir to be taken twice a day (4 tablets of 200 mg each in the
morning and 4 in the evening)
Symptoms of favipiravir overdose include the following:
Decrease in locomotor activities such as walking or running
Contact the poison information emergency number or go to the nearest hospital for immediate
treatment in case of an overdose.
In case of a missed dose, take your next dose at the normal time, and continue with your regular
Warnings and Precautions
Caution is advised in individuals with gout or any other abnormalities in uric acid metabolism.
Possible Side Effects
Favipiravir is teratogenic; it can cause developmental problems in the foetus. Thus, it should be
avoided in women with confirmed or suspected pregnancy.
A study performed in Russia on 390 participants with COVID-19 demonstrated that fever had
resolved in three days in 68% of the participants taking favipiravir compared to fever resolution in
6 days on standard treatment. The RT-PCR test was negative in 65% of the participants on favipiravir
on the fourth day of treatment and negative for 90% of the participants on the tenth day of
In another study that was conducted in Japan on 2,141 participants with mild-to-moderate
COVID-19, it was observed that 74% of the patients showed improvement by the end of the first
week and 88% of the patients showed improvement by the end of the second week.
In a study conducted on 80 participants with COVID-19 in China, chest CT showed improved in 91.4%
participants compared to 62.2% of the participants who were administered lopinavir/ritonavir.
Thus, in people with mild-to-moderate COVID-19 infection, favipiravir rapidly decreases fever,
lowers the viral load, shows clearance of the chest CT and leads to faster recovery overall.
When should it not be used?
Avoid using the drug in people with the following conditions:
If you are allergic to favipiravir
If you have severe hepatic or renal impairment
In pregnant and lactating women